GSK - NYSE - Nasty Chart, looks like a test of the 2012 low is coming. GlaxoSmithKline ($GSK) is making big cost cuts to boost its finances next year as sales of its $8.25 billion asthma med Advair are deflated by competition, generic and otherwise. With the U.S. being the biggest market for the [...]
We have bad news and good news about patent expirations next year. The bad? When you tot up the billions of sales at risk of patent expiration in 2015, the result is $44 billion, the biggest number since the debacle of 2012. That year, $53 billion worth of drugs fell off patent--and many drugmakers are [...]
LONDON and PITTSBURGH, Dec. 4, 2014 /PRNewswire/ -- Mylan Inc. (MYL) today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) for its New Drug Applications (NDAs) for two dosages of abacavir/lamivudine tablets for oral suspension for the treatment of HIV-1 infection in paediatric patients. [...]
The world spends most of its money on medicine. New study reveals that by the year 2018 the world drug bill will reach approximately $1.3 trillion. The new treatments for cancer and hepatitis C contribute to the rise. Another factor for this increase are the people that buy pharmaceuticals using their rising incomes. The new [...]
